^
BIOMARKER:

ALK fusion

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
ALK fusion
NSCLC
lorlatinib
Sensitive: A2 - Guideline
ALK fusion
NSCLC
ALK inhibitor
Sensitive: A2 - Guideline
ALK fusion
Melanoma
crizotinib
Sensitive: A2 - Guideline
ALK fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
ALK fusion
Lung Non-Squamous Non-Small Cell Cancer
brigatinib
Sensitive: A2 - Guideline
ALK fusion
Lung Non-Squamous Non-Small Cell Cancer
alectinib
Sensitive: A2 - Guideline
ALK fusion
NSCLC
crizotinib
Sensitive: B - Late Trials
ALK fusion
NSCLC
alectinib
Sensitive: C2 – Inclusion Criteria
ALK fusion
NSCLC
anlotinib
Sensitive: C3 – Early Trials
ALK fusion
NSCLC
ceritinib
Sensitive: C3 – Early Trials
ALK fusion
Colorectal Adenocarcinoma
ceritinib
Sensitive: C3 – Early Trials
ALK fusion
NSCLC
pemetrexed
Resistant: C3 – Early Trials
ALK fusion
LUAD
crizotinib
Sensitive: C4 – Case Studies
ALK fusion
Glioma
lorlatinib
Sensitive: C4 – Case Studies
ALK fusion
T Cell Non-Hodgkin Lymphoma
gilteritinib
Sensitive: D – Preclinical